The Department of Justice executed a definitive strike against the genetic testing sector on June 30, 2025. This enforcement action exposed a criminal apparatus that had extracted $1.17 billion from federal health care programs. Prosecutors charged 49 defendants. These individuals orchestrated schemes involving fraudulent claims for cancer genomics (CGx) and pharmacogenomics (PGx). The operation confirmed that genetic testing laboratories have displaced toxicology clinics as the primary engine of Medicare fraud. This 2025 takedown targeted a specific mechanism: the coupling of aggressive telemarketing with rubber-stamped telemedicine prescriptions to bill for medically unnecessary DNA analysis.

Federal investigators identified a clear pattern in the submitted claims. Laboratories billed Medicare for high-tier molecular pathology codes without treating physician involvement. The 2025 data reveals that genetic testing accounted for 43 percent of all Medicare Part B laboratory reimbursement in 2024. This equates to $3.6 billion. Yet genetic tests represented only 5 percent of the total volume. This inverse ratio of low volume to high cost made the sector a prime target for exploitation. The DOJ investigation found that illicit networks focused on two specific categories. CGx testing screens for hereditary cancer syndromes. PGx testing analyzes drug metabolism rates. Both have legitimate clinical uses. Criminal actors weaponized them to bypass medical necessity requirements.